UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K/A
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of February, 2020
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
 
GlaxoSmithKline plc
 
GSK publishes provisional dividend dates
 
 
 
The following amendment has been made to the 'GSK publishes 2020 Dividend Dates' announcement released on 8 January 2020.
 
Q1 2020 Last date for DRIP elections amended to 18 June 2020.
 
All other details remain unchanged.
 
The full amended text is shown below.
 
 
Results
announcement
date
Ex-dividend
date
Record date
Last date for
DRIP elections
Payment date
Q1 2020
 Wednesday
29 April
Thursday
14 May
Friday
15 May
Thursday
18 June
 
Thursday
9 July
 
Q2 2020
 Wednesday
29 July
Thursday
13 August
Friday
14 August
Thursday
17 September
 
Thursday
8 October
 
Q3 2020
 Wednesday
28 October
Thursday
12 November
Friday
13 November
Monday
21 December
 
Thursday
14 January 2021
 
Q4 2020
(Final)
 Wednesday
3 February 2021
Thursday
18 February 2021
Friday
19 February 2021 
Tuesday  
16 March 2021
 
Thursday
8 April 2021
 
 
These dates are indicative and may be subject to change. 
 
 
 
 
Victoria Whyte
Company Secretary
 
3 February 2020
 
 
 
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: February 03, 2020 
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc